Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride.
In a prospective, randomized, double-blind, placebo-controlled, cross-over study of forty-one patients we found that oral ingestion of 1,248 mg a day of L-Lysine monohydrochloride shows evidence of decreasing the recurrence rate of herpes simplex attacks in nonimmunocompromised hosts. A dose of 624 mg a day was not effective. L-Lysine may also be capable of decreasing the severity of symptoms associated with recurrences. Neither dosage showed any evidence of shortening the healing time compared to placebo.
D000284:Administration, Oral; D001120:Arginine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004573:Electrolytes / Q000097:blood; D006561:Herpes Simplex / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008239:Lysine / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D012008:Recurrence
D004573:Electrolytes; D001120:Arginine; D008239:Lysine